From: Possible Anandamide and Palmitoylethanolamide involvement in human stroke
 | Group A | Group B | p |
---|---|---|---|
Sex (M/F) | 5/5 | 4/4 | n.s. |
Age yrs. (mean ± SD) | 70 ± 13 | 70 ± 12 | n.s. |
NIHSS score (median ± SD; range) | 22 ± 10; 3-29 | - | - |
Fugl-Meyer Scale-arm score (median ± SD; range) | 11.50 ± 9; 8-44 | - | - |
CT ischemic area Volume (mL; mean ± SD) | 76.10 ± 43.46 | - | - |
Body Mass Index (mean ± SD) | 25.20 ± 2.74 | 24.63 ± 2.39 | n.s. |
Cholesterol (mmol/L - mean ± SD) | 11.69 ± 2.31 | 11.64 ± 2.04 | n.s. |
Triglycerides (mmol/L - mean ± SD) | 6.97 ± 2.33 | 6.82 ± 1.00 | n.s. |
Blood Glucose (mmol/L - mean ± SD) | 5.61 ± 0.71 | 5.77 ± 0.74 | n.s. |
AEA T0 (pmol/lipid mg - mean ± SD) | 3.42 ± 2.71 | 1.81 ± 1.53 | 0.026 |
AEA T1 (pmol/lipid mg - mean ± SD) | 2.87 ± 2.34 | - | n.s. |
AEA T2 (pmol/lipid mg - mean ± SD) | 3.11 ± 2.72 | - | n.s. |
PEA TO (pmol/lipid mg - mean ± SD) | 2.47 ± 0.96 | 2.05 ± 0.31 | n.s. |
PEA T1 (pmol/lipid mg - mean ± SD) | 2.28 ± 1.01 | - | n.s. |
PEA T2 (pmol/lipid mg - mean ± SD) | 2.17 ± 0.67 | - | n.s. |
2-AG T0 (pmol/lipid mg - mean ± SD) | 3.42 ± 7.22 | 6.80 ± 9.50 | n.s. |
2-AG T1 (pmol/lipid mg - mean ± SD) | 4.65 ± 4.98 | - | n.s. |
2-AG T2 (pmol/lipid mg - mean ± SD) | 3.29 ± 3.10 | - | n.s. |